Imbruvica (ibrutinib) / Generic mfg., AbbVie, J&J 
Welcome,         Profile    Billing    Logout  

130 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imbruvica (ibrutinib) / AbbVie, J&J
NCT03190330: A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Completed
4
75
RoW
Ibrutinib 420 mg, Imbruvica, Ibrutinib 560 mg
Johnson & Johnson Private Limited
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
05/23
05/23
NCT04042376: A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Completed
4
17
RoW
Ibrutinib, JNJ-54179060, PCI-32765
Janssen Research & Development, LLC
Waldenstrom Macroglobulinemia
03/24
03/24
NCT03229200 / 2016-004356-30: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Enrolling by invitation
4
600
Europe, Canada, US, RoW
Ibrutinib
Pharmacyclics Switzerland GmbH, Janssen Biotech, Inc., including Johnson & Johnson
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
05/27
05/27
2014-001363-12: Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

Ongoing
3
870
Europe, RoW
Ibrutinib, PCI-32765, Capsule, hard, Imbruvica
Klinikum der Universität München, Medizinische Klinik und Poliklinik III, HOVON Foundation, KroHem, Janssen Pharmaceutica NV, Skåne University Hospital, Department of Oncology, Dutch Cancer Society
Generalized mantle cell Lymphoma, Generalized mantle cell Lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
REACH3, NCT03112603 / 2016-004432-38: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation

Checkmark Data from REACH3 trial for acute GVHD at ASH 2020
Dec 2020 - Dec 2020: Data from REACH3 trial for acute GVHD at ASH 2020
Checkmark Data from REACH3 trial in steroid-refractory chronic GVHD
Jul 2020 - Jul 2020: Data from REACH3 trial in steroid-refractory chronic GVHD
Completed
3
330
Europe, Canada, Japan, US, RoW
Ruxolitinib, Jakafi, INCB018424, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Incyte Corporation
Graft-versus-host Disease (GVHD)
05/20
12/22
ELEVATE-RR, NCT02477696 / 2014-005530-64: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Checkmark Presentation of data from ELEVATE-RR trial in r/r CLL at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from ELEVATE-RR trial in r/r CLL at ASH 2022
Checkmark From ELEVATE-RR trial in r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From ELEVATE-RR trial in r/r CLL at ASH 2021
Checkmark From ELEVATE-RR trial in combination with Ibrutinib for previously Treated Patients With CLL
More
Active, not recruiting
3
533
Europe, US, RoW
Acalabrutinib, ACP-196, Ibrutinib
Acerta Pharma BV
Chronic Lymphocytic Leukemia
09/20
01/28
GLOW, NCT03462719 / 2017-004699-77: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Checkmark New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Dec 2021 - Dec 2021: Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Checkmark Presentation of data from GLOW trial in combination with Venclexta for CLL/SLL at EHA 2021
More
Active, not recruiting
3
211
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Janssen Research & Development, LLC, Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell
02/21
04/27
SHINE , NCT01776840 / 2012-004056-11: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Checkmark Data from SHINE trial in 1L MCL at ASCO 2022
Jun 2022 - Jun 2022: Data from SHINE trial in 1L MCL at ASCO 2022
Checkmark From SHINE trial in 1L MCL
Mar 2022 - Mar 2022: From SHINE trial in 1L MCL
Active, not recruiting
3
523
Europe, Canada, Japan, US, RoW
Bendamustine, Rituximab, Ibrutinib, Placebo
Janssen Research & Development, LLC, Pharmacyclics LLC.
Mantle Cell Lymphoma
06/21
06/24
2020-004553-72: A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in patients with previously treated Mantle Cell Lymphoma

Not yet recruiting
3
500
Europe, RoW
pirtobrutinib, Ibrutinib, [na], [LOXO-305], Film-coated tablet, Tablet, IMBRUVICA
Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, LOXO ONCOLOGY INCORPORATED, Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc
Mantle cell lymphoma, a cancer of white blood cells (developing in a certain part of the lymph node), which help the body fight infections, Diseases [C] - Cancer [C04]
 
 
SELENE , NCT01974440 / 2013-003093-27: A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Hourglass Jul 2022 - Dec 2022 : Data from SELENE trial for follicular lymphoma/MZL
Completed
3
405
Europe, Japan, US, RoW
Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma
05/22
06/23
2021-003206-41: A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL

Ongoing
3
650
Europe
Pirtobrutinib, Ibrutinib, LOXO-305, Tablet, Capsule, hard, IMBRUVICA
Loxo Oncology, Inc., Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma krónikus limfocitás leukémia / kis limfocitás limfóma, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years, Diseases [C] - Cancer [C04]
 
 
ALPINE, NCT03734016 / 2018-001366-42: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Checkmark Data from ALPINE trial for CLL at ASH 2022
Dec 2022 - Dec 2022: Data from ALPINE trial for CLL at ASH 2022
Completed
3
652
Europe
Zanubrutinib, BGB-3111, Brukinsa, Ibrutinib, Imbruvica
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/22
02/24
2022-001547-25: A Phase 3 study of Zilovertamab in addition to Ibrutinib in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Estudio en fase III de zilovertamab en combinación con ibrutinib en pacientes con linfoma de células del manto recidivante o resistente

Ongoing
3
365
Europe
Zilovertamab, Ibrutinib, Zilovertamab, PCI-32765, Solution for infusion, Capsule, hard
Oncternal Therapeutics, Inc, Oncternal Therapeutics, Inc
Relapsed or Refractory Mantle Cell Lymphoma Linfoma de células del manto recidivante o resistente, Mantle Cell Lymphoma Linfoma de células del manto, Diseases [C] - Cancer [C04]
 
 
NCT01724346 / 2012-003968-44: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
3
232
Europe, Canada, US, RoW
Post-Chlorambucil Therapy Follow-up, Ibrutinib, PCI-32765, Second-line Ibrutinib, Alternative Anticancer Treatment, Alternative Anti-cancer Treatment
Pharmacyclics LLC., Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
08/23
BELLWAVE-011, NCT06136559: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/)

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Nemtabrutinib, MK-1026, ARQ 531, Ibrutinib, Acalabrutinib
Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
09/32
09/32
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
NCT04212013: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Active, not recruiting
3
23
US
Ibrutinib, Rituximab, Placebo
Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC.
Marginal Zone Lymphoma
06/24
03/27
SYMPATICO, NCT03112174 / 2017-000129-12: Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma

Jan 2023 - Dec 2023: Data from SYMPATICO trial in combination with Venclexta for r/r MCL
Active, not recruiting
3
352
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
Pharmacyclics LLC., Janssen Research & Development, LLC
Mantle-Cell Lymphoma
11/24
11/24
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
PERSPECTIVE, NCT02947347 / 2016-003202-14: Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Active, not recruiting
3
445
Europe, Canada, US, RoW
ibrutinib, Imbruvica, placebo to match ibrutinib, rituximab
Pharmacyclics LLC.
Follicular Lymphoma
06/26
06/26
NCT05431179 / 2022-001547-25: A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Withdrawn
3
365
NA
Zilovertamab, Cirmtuzumab, UC961, Ibrutinib, Imbruvica, Placebo
Oncternal Therapeutics, Inc, Pharmacyclics LLC.
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Diseases, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
11/26
12/26
NCT01804686 / 2012-004225-24: A Long-term Extension Study of PCI-32765 (Ibrutinib)

Enrolling by invitation
3
700
Europe, Canada, Japan, US, RoW
Ibrutinib, PCI-32765
Janssen Research & Development, LLC, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
12/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
02/25
08/28
2022-000364-21: A Study of Ibrutinib in Combination With Rituximab Versus Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab, in Relapsed/Refractory Mantle Cell Lymphoma Estudio de ibrutinib en combinación con rituximab frente a lenalidomida más rituximab o bortezomib más rituximab para el tratamiento de linfoma de células del manto recidivante/refractario.

Completed
2/3
490
Europe, RoW
ibrutinib, JNJ-54179060, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection, IMBRUVICA, Ruxience, Lenalidomide Accord, VELCADE
Janssen-Cilag International NV, Janssen Research & Development, LLC
Relapsed or Refractory Mantle Cell Lymphoma Linfoma de células del manto recidivante o refractario, Blood Cancer Cáncer de sangre, Diseases [C] - Cancer [C04]
 
 
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting
2/3
148
Europe
Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
University College, London, Janssen-Cilag Ltd.
Waldenstrom Macroglobulinemia
03/30
03/30
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B.

Not yet recruiting
2
90
Europe
Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag
Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2015-002855-85: A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years.

Ongoing
2
170
Europe
Decitabine, ibrutinib, Powder for concentrate for solution for infusion, Capsule, soft, Dacogen, Imbruvica
HOVON Foundation, Dutch Cancer Society, Janssen-Cilag International NV
Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes, Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes, Diseases [C] - Cancer [C04]
 
 
2012-003608-11: Assessing how the drug ibrutinib works in Chronic Lymphocytic Leukaeamia.

Ongoing
2
40
Europe
Ibrutinib, PCI-32765,
University of Birmingham, LLR, Pharmacyclics
Chronic Lymphocytic leukaemia
 
 
2015-005454-35: An early phase study using a response based combination therapy of rituxumab and ibrutinib in patients with post-transplant lymphoproliferative disorder (PTLD)

Ongoing
2
60
Europe
Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone, Vincristine, Capsule, hard, Infusion, Oral solution, Imbruvica, MabThera, Myocet, Prednisolone
University of Birmingham, Bloodwise, Janssen
Post-transplant lymphoproliferative disorder, Post-transplant lymphoproliferative disorder, Diseases [C] - Cancer [C04]
 
 
2016-004707-32: Clinical trial with Ibrutinib and Venetoclax for patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Studio Clinico con Ibrutinib e Venetoclax per pazienti con Leucemia Linfatica Cronica Recidivante o Refrattaria

Ongoing
2
31
Europe
VENETOCLAX, [ABT-199], Film-coated tablet
OSPEDALE SAN RAFFAELE, Abbvie
Relapsed or Refractory Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica Recidivante o Refrattaria, Chronic Lymphocytic Leukemia relapsed or refractory to previous treatments Leucemia Linfatica Cronica ricaduta o non responsiva ai trattamenti precedenti, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2016-002599-29: A trial evaluating treatment with ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL)

Ongoing
2
230
Europe
venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, ibrutinib, Tablet, Capsule, hard, Venclyxto, Imbruvica
HOVON Foundation, AbbVie, Janssen
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
2017-003256-22: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma Ibrutinib und Standard-Immunochemotherapie (R-CHOEP-14) in jungen Hochrisiko- Patienten mit diffusem großzelligem B-Zell-Lymphom

Not yet recruiting
2
40
Europe
Capsule, hard, IMBRUVICA 140 mg hard capsules
Universitätsklinikum Münster, Janssen-Cilag GmbH
diffuse large B-cell lymphoma diffuses großzelliges B-Zell-Lymphom, malignant disease of the lymphatic system bösartige Erkrankung des lymphatischen Systems, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-001099-49: therapy with ibrutinib for patients with Chronic lymphocytic leukemia with subclonal TP53 aberrations terapia con Ibrutinib per pazienti affetti da leucemia linfatica cronica che presentano alterazioni subclonali di TP53

Ongoing
2
185
Europe
ibrutinib, [PCI-32765], Capsule, hard
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
Chronic Lymphocytic Leukemia (CLL) leucemia linfatica cronica (LLC), Chronic Lymphocytic Leukemia never treated leucemia linfatica cronica mai trattata, Diseases [C] - Cancer [C04]
 
 
2017-005137-23: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with (ABC) DLBCLat intermediate-high and high risk Terapia R-CHOP in combinazione con ibrutinib e successivo mantenimento con ibrutinib in pazienti non trattati con linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto.

Not yet recruiting
2
90
Europe
Ibrutinib, IMP1, Capsule, hard, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (120 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen-Cilag S.p.A
Activated-B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk (IPI =2) Linfoma diffuso a grandi cellule B con profilo ABC (Activated-B-Cell) e rischio intermedio/alto o alto (IPI = 2), B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk Linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
GELTAMO-IMCL-2015, NCT02682641 / 2015-004158-17: Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Active, not recruiting
2
50
Europe
IBRUTINIB, Imbruvica, Rituximab
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A.
Mantle Cell Lymphoma
12/19
12/24
2018-002364-44: Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas

Ongoing
2
175
Europe
MabThera Uso sottocutaneo, MabThera, Imbruvica, [NA], Solution for injection, Concentrate for solution for infusion, Capsule, hard, MabThera, Imbruvica
IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP, Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Previously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatment, Previously untreated marginal zone lymphoma, Diseases [C] - Cancer [C04]
 
 
2015-003128-30: Ibrutinib in relapsed lymphocyte-predominant Hodgkin lymphoma Ibrutinib zur Behandlung des rezidivierten nodulär Lymphozyten-prädominanten Hodgkin Lymphom

Not yet recruiting
2
36
Europe
Capsule, hard, Imbruvica
University of Cologne, JANSSEN-CILAG GmbH
relapsed lymphocyte-predominant Hodgkin lymphoma rezidiviertes nodulär Lymphozyten-prädominantes Hodgkin Lymphom, relapsed Hodgkin lymphoma (cancer of lymphatic system) Rückfall eines Hodgkin Lymphoms (Krebserkrankung des lymphatischen Systems), Diseases [C] - Cancer [C04]
 
 
2019-003632-23: Lenalidomide and Ibrutinib in association with R-MPV first-line treatment of Primary Central Nervous System Lymphoma for patients aged 18 to 60 Lénalidomide et Ibrutinib en association avec le R-MPV en traitement d’induction de première ligne pour les patients âgés de 18 à 60 ans présentant un lymphome primitif du système nerveux central (LCP).

Not yet recruiting
2
128
Europe
Ibrutinib 140 mg, Rituximab, Methotrexate, Procarbazine, Vincristine, Prednisone, Capsule, hard, Solution for infusion, Capsule, Tablet, Revlimid 5 mg, Revlimid 10 mg, Imbruvica 140 mg
Institut Curie, PHRC-K 2018 Public Health Grant, CELGENE SAS, JANSSEN-CILAG, KEOCYT SAS
Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, en traitement de première ligne, Primary Central Nervous System Lymphoma in patients aged 18 to 60, first treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, 1er traitement, Diseases [C] - Cancer [C04]
 
 
2019-004948-30: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Not yet recruiting
2
200
Europe
parsaclisib 20 mg Tablets, parsaclisib 5 mg Tablets, parsaclisib 2.5 mg Tablets, parsaclisib 1 mg Tablets, INCB050465 20 mg Tablets, INCB050465 5 mg Tablets, INCB050465 2.5 mg Tablets, INCB050465 1 mg Tablets, Tablet, IMBRUVICA 140 mg hard capsules
Incyte Corporation, INCYTE CORPORATION, Incyte Corporation
Advanced malignancies, Advanced malignancies, Diseases [C] - Cancer [C04]
 
 
ACE-CL-208, NCT02717611 / 2015-005317-68: A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Hourglass Jan 2020 - Dec 2020 : From ACE-CL-208 trial in r/r CLL
Active, not recruiting
2
60
Europe, US, RoW
ACP-196 (acalabrutinib), Acalabrutinib
Acerta Pharma BV
Chronic Lymphocytic Leukemia
10/20
09/26
CAPTIVATE, NCT02910583 / 2016-002293-12: Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Checkmark New data from the P2 CAPTIVATE study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P2 CAPTIVATE study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark Data from CAPTIVATE trial in combination with Venclexta for CLL at ASH 2021
Dec 2021 - Dec 2021: Data from CAPTIVATE trial in combination with Venclexta for CLL at ASH 2021
Checkmark presenting data from CAPTIVATE trial in combination with Venclexta for CLL/SLL at EHA 2021
More
Completed
2
323
Europe, US, RoW
ibrutinib, venetoclax, Placebo
Pharmacyclics LLC., Janssen Research & Development, LLC
Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
11/20
03/24
NCT03267186: Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Completed
2
8
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis
Andrew Rezvani, National Institutes of Health (NIH), Pharmacyclics LLC.
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient
04/21
04/21
2020-004910-37: Study to compare the efficacy and safety of the combinaison of venetoclax+ibrutinib in patients with untreated mantle cell lymphoma

Not yet recruiting
2
194
Europe
ibrutinib, venetoclax, ABT - 199, Capsule, hard, Tablet, Imbruvica, Venclyxto
LYSARC, Janssen Pharmaceutica NV, Abbvie Inc
Untreated mantle cell lymphoma, Untreated mantle cell lymphoma, Diseases [C] - Cancer [C04]
 
 
2020-004409-30: Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemia Trattamento con venetoclax consolidato con ibrutinib e rituximab per aumentare possibilità di malattia minima residua in paziente con leucemia linfatica cronica

Not yet recruiting
2
55
Europe
venclyxto, [venclyxto], Modified-release tablet, Venclyxto
OSPEDALE SAN RAFFAELE, AbbVie
Previously Untreated Chronic Lymphophatic Leukaemia Leucemia Linfatica Cronica non precedentemente trattata, Previously untreated low-risk blood cancer Tumore del sangue a basso rischio, non precedentemente trattato, Diseases [C] - Cancer [C04]
 
 
2021-000311-23: Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Ibrutinib e Obinutuzumab come trattamento di prima linea per pazienti affetti dalla Leucemia Linfatica Cronica

Not yet recruiting
2
53
Europe
NA, Gazyvaro, [NA], [Gazyvaro], Capsule, hard, Concentrate for solution for injection, imbruvica, gazyvaro
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, Diseases [C] - Cancer [C04]
 
 
NCT04062448: A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Completed
2
16
Japan
Ibrutinib, PCI-32765, Rituximab
Janssen Pharmaceutical K.K.
Waldenstrom Macroglobulinemia
08/21
03/23
NCT02242097: Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
37
US
ibrutinib, Bruton's tyrosine kinase inhibitor PCI-32765, BTK inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, laboratory biomarker analysis
Northwestern University, Janssen Scientific Affairs, LLC, National Cancer Institute (NCI)
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
01/23
01/25
NCT04477486: Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Active, not recruiting
2
6
Japan
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclexta, GDC-0199, Venclyxto
AbbVie
Mantle Cell Lymphoma (MCL)
02/22
10/25
NCT02689869 / 2014-005164-15: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Active, not recruiting
2
98
Europe
Ibrutinib, Imbruvica, GA 101, Obinutuzumab
Ludwig-Maximilians - University of Munich, Hoffmann-La Roche, Janssen-Cilag G.m.b.H
Indolent Non-Hodgkin Lymphoma
04/22
07/22
MIT, NCT04514393: Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Recruiting
2
33
RoW
Methotrexate, MTX, Ibrutinib, Imbruvica, Temozolomide, TMZ
Huiqiang Huang, Guangdong 999 Brain Hospital, Nanfang Hospital of Southern Medical University, Xian-Janssen Pharmaceutical Ltd.
Primary Central Nervous System Lymphoma, PCNSL, Non Hodgkin Lymphoma
09/22
06/24
NCT03620903 / 2017-004362-95: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Active, not recruiting
2
53
Europe
Ibrutinib / Bortezomib / Rituximab, Imbruvica / Velcade / Mabthera
Christian Buske, University of Ulm, ClinAssess GmbH, Zentrum für Klinische Studien Ulm, Hoffmann-La Roche, Johnson & Johnson
Waldenstrom Macroglobulinemia
11/22
09/29
NCT04235036: Ibrutinib and Rituxan for Chronic GVHD

Terminated
2
19
US
Rituximab, Ibrutinib
Northside Hospital, Inc., Pharmacyclics LLC.
Graft Vs Host Disease
12/22
12/22
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms.

Not yet recruiting
2
150
Europe
Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV
Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04]
 
 
NCT02643667: Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Completed
2
27
US
Ibrutinib, Radical prostatectomy
Washington University School of Medicine, Pharmacyclics LLC.
Prostate Cancer
04/23
04/23
NCT04273139: Ibrutinib + Venetoclax in Untreated WM

Active, not recruiting
2
45
US
IBRUTINIB, Imbruvica, Venetoclax, Venclexta
Dana-Farber Cancer Institute, AbbVie, Pharmacyclics LLC.
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation
06/22
02/28
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Recruiting
2
90
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
06/24
07/27
NCT02955628: RICE-ibrutinib in Relapsed DLBCL

Recruiting
2
34
RoW
Ibrutinib-RICE, Imbruvica
Singapore General Hospital, Janssen, LP
Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent
08/23
08/23
NCT02532257: Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Completed
2
46
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Janssen, LP
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, CD20 Positive, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
08/23
08/23
NCT02997761: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Recruiting
2
20
US
Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765
Brian Jonas, National Cancer Institute (NCI), Pharmacyclics LLC.
Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
02/25
09/25
NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting
2
40
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc.
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
10/24
04/25
NCT02207062: Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Completed
2
20
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Laboratory Biomarker Analysis
University of Washington, Janssen Pharmaceuticals
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
11/23
11/23
NCT02623010: Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

Recruiting
2
30
RoW
Imbruvica, Ibrutinib, JNJ-54179060
Rabin Medical Center, Janssen, LP
Central Nervous System Lymphoma
12/23
12/23
17P.176, NCT03198026: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Recruiting
2
30
US
Ibrutinib, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, 936563-96-1, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, Gazyva, R7159, RO 5072759, GA-101, GA101, huMAB(CD20), RO-5072759, RO5072759, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Genentech, Inc., Pharmacyclics LLC.
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
12/24
02/31
R-CHOEP-brut, NCT03399513: Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

Completed
2
40
Europe
Ibrutinib Oral Capsule [Imbruvica], R-CHOEP chemotherapy
University Hospital Muenster, Janssen-Cilag G.m.b.H
Diffuse Large B Cell Lymphoma
12/23
12/23
ERADIC, NCT04010968: Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

Active, not recruiting
2
120
Europe
venetoclax and ibrutinib (I+VEN), FCR
French Innovative Leukemia Organisation, AbbVie, Janssen-Cilag Ltd.
Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy
12/23
06/26
NCT02005289: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Checkmark From combination trial with lenalidomide in CLL
Nov 2016 - Nov 2016: From combination trial with lenalidomide in CLL
Checkmark Combination with lenalidomide in CLL at ASH 2015
Dec 2015 - Dec 2015: Combination with lenalidomide in CLL at ASH 2015
Checkmark Final results in CLL/SL
More
Active, not recruiting
2
41
US
MOR00208, anti-CD19 MAb XmAb5574, anti-CD19 MoAb XmAb5574, XmAb5574, lenalidomide, CC-5013, IMiD-1, Revlimid, Correlative Studies, laboratory biomarker analysis
Ohio State University Comprehensive Cancer Center, MorphoSys AG
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
12/24
12/24
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
NCT02518555: Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
2
42
US
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Ibrutinib, PCI-32765, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, PCV13 Vaccine, Prevnar 13, Quality-of-Life Assessment, Quality of Life Assessment, Trivalent Influenza Vaccine, Flu prevention, Flu prophylaxis, Flu shot, Flu vaccination, Fluarix, Fluzone, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV
Jennifer Woyach, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/24
NCT03646461: Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Active, not recruiting
2
5
US
Ibrutinib 560mg PO daily (Imbruvica), Imbruvica, Cetuximab, Erbitux, Nivolumab, opdivo
University of California, San Diego, Pharmacyclics LLC.
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
01/25
05/25
VEGA, NCT05564052 / 2022-000364-21: A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
36
Europe, US, RoW
Ibrutinib, JNJ-54179060, IMBRUVICA, PCI-32765, Lenalidomide, Rituximab, Bortezomib
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma, Mantle-Cell
12/23
09/24
NCT03478514: Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

Active, not recruiting
2
39
US
Palbociclib, Ibrance; PD-0332991, Ibrutinib, Imbruvica
Alliance Foundation Trials, LLC., Pfizer
Mantle Cell Lymphoma, B Cell Lymphoma
06/25
12/25
IDA53, NCT03734198: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Active, not recruiting
2
29
Europe
Ibrutinib, Ibrutinib treatment, Daratumumab, Daratumumab perfusion
French Innovative Leukemia Organisation, Janssen, LP
Relapsed or Refractory Chronic Lymphocytic Leukemia
06/24
06/26
BDHRT001, NCT04992377: R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Not yet recruiting
2
30
RoW
R-EPOCH in Combination With Ibrutinib
Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd.
Richter Transformation
08/24
08/25
NCT04509700: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Recruiting
2
200
Europe, Japan, US, RoW
Parsaclisib, INCB050465, parsaclisib + itacitinib, INCB39110, parsaclisib + ruxolitinib, INCB018424, parsaclisib + ibrutinib
Incyte Corporation
B-Cell Malignancies
09/24
09/24
NCT02251548: A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
85
US
Ibrutinib, Imbruvica™, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Neosar®, Rituximab, Rituxan®
Dana-Farber Cancer Institute, Pharmacyclics LLC., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership
Chronic Lymphocytic Leukemia, Leukemia
01/25
01/26
NCT03207555: Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
2
29
US
Ibrutinib, PCI-32765, Imbruvica
M.D. Anderson Cancer Center, Pharmacyclics LLC.
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
08/25
08/25
NCT05105841: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
2
20
Japan
Venetoclax, Venclexta, ABT-199, GDC-0199, Ibrutinib, Imbruvica, Obinutuzumab, GA101, Gazyva, RO5072759
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/25
BGB-3111-215 , NCT04116437: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Recruiting
2
90
US
Zanubrutinib, BGB-3111, BRUKINSA
BeiGene
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
10/25
10/25
TARMAC, NCT04234061: Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

Active, not recruiting
2
20
RoW
ibrutinib and Tisagenlecleucel
Peter MacCallum Cancer Centre, Australia, Novartis
Mantle Cell Lymphoma Recurrent
09/27
09/30
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Recruiting
2
99
Europe
Carfilzomib + Ibrutinib, Ibrutinib
Christian Buske, Amgen, Janssen, LP
Waldenstrom Macroglobulinemia
02/28
02/28
NCT05998642: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Recruiting
2
30
Canada
Methotrexate, Rituximab (where available), Ibrutinib
Canadian Cancer Trials Group, Janssen Inc.
Non-hodgkin Lymphoma
05/28
12/28
TAILOR, NCT05963074: A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
2
320
Europe, Canada, US, RoW
Ibrutinib, JNJ-54179060, IMBRUVICA, Venetoclax, VENCLEXTA, VENCLYXTO
Janssen Research & Development, LLC, Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
09/28
03/29
EPCORE NHL-5, NCT05283720 / 2021-005725-24: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Recruiting
2
394
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013;, Lenalidomide, Ibrutinib, Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, Venetoclax, Venclexta;, ABT-199, GDC-0199, CC-99282
Genmab, AbbVie
Non-Hodgkin Lymphoma
11/32
11/32
2013-000771-33: A phase Ib study of ibrutinib combined with R-DHAP or R-DHAOx in patients with B-cell lymphomas. Etude de phase Ib de l’ibrutinib combiné avec R-DHAP ou R-DHAOx chez des patients atteints d’un lymphome à cellules B

Ongoing
1/2
84
Europe
ibrutinib, ibrutinib, Capsule, hard
LYSARC, Janssen Pharmaceutica NV
Patients with any type of relapsed or refractory B-cell lymphoma will be eligible in groups A and B (during the dose escalation and the expansion parts of the study) and untreated patients with mantle cell lymphoma will be eligible for group C (only during the expansion part of the study) Les patients atteints de n’importe quel type de lymphome à cellules B en rechute ou réfractaire seront éligibles pour les groupes A et B pendant les phases d’escalade de dose et d’expansion de l’étude, et les patients atteints d’un lymphome à cellules du manteau non préalablement traité seront éligibles pour le groupe C uniquement pendant la phase d’expansion, B-cell lymphomas lymphome diffus à grandes cellules B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
OAsIs, NCT02558816 / 2014-003740-13: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

Active, not recruiting
1/2
48
Europe
Ibrutinib + GA101 +GDC-0199, GA101 : Obinutuzumab, Ibrutinib, GDC-0199
Nantes University Hospital, Janssen, LP, Roche Pharma AG
Mantle Cell Lymphoma
04/19
10/25
2018-004336-30: Study of YTB323 in adult patients with CLL/SLL, 3 L + DLBCL, ALL and 1L HR LBCL.

Not yet recruiting
1/2
224
Europe
Rapcabtagene autoleucel, YTB323, Dispersion for infusion, Capsule, hard, Film-coated tablet, IMBRUVICA
Novartis Pharma AG, Novartis Pharma AG
ALL, CLL/SLL and DLBCL, and High-Risk LBCL., Acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and High-Risk large B-cell lymphoma (HR LBCL)., Diseases [C] - Cancer [C04]
 
 
PrE0404, NCT03323151: A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Completed
1/2
43
US
Ixazomib, Ninlaro, Ibrutinib, Imbruvica
PrECOG, LLC., Takeda
Mantle-Cell Lymphoma
09/22
09/23
2022-000891-20: An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Hematologic Malignancies Estudio abierto, con escalado de dosis y expansión de dosis, para evaluar la seguridad, la farmacocinética, la farmacodinámica y la actividad clínica del CA‑4948 administrado por vía oral en pacientes con neoplasias hematológicas en recaída o refractarias

Not yet recruiting
1/2
221
Europe
Ibrutinib, CA-4948, Film-coated tablet, Imbruvica
Curis, Inc., Curis, Inc.
Relapsed or Refractory Hematologic Malignancy Neoplasias hematológicas en recaída o refractarias, Relapsed or Refractory Hematologic Malignancy Neoplasias hematológicas en recaída o refractarias, Diseases [C] - Cancer [C04]
 
 
PLATFORM, NCT03310619: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Checkmark PLATFORM trial in combination with JCAR017
Sep 2018 - Sep 2018: PLATFORM trial in combination with JCAR017
Completed
1/2
62
US
JCAR017, Durvalumab, MEDI4736, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Celgene
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
02/23
02/23
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
08/24
03/25
NCT02315768: Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Active, not recruiting
1/2
32
US
GA101, Obinutuzumab, ibrutinib
University of California, San Diego, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
11/23
11/23
NCT02927964: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Completed
1/2
21
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, TLR9 Agonist SD-101, ISS-ODN SD-101, SD-101
Robert Lowsky, Janssen, LP, National Cancer Institute (NCI), The Leukemia and Lymphoma Society, Rising Tide Foundation
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
05/23
05/23
NCT02956382: Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Active, not recruiting
1/2
24
US
Ibrutinib, PCI-32765, Venetoclax, ABT-199
Georgetown University, AbbVie, Pharmacyclics LLC., Hackensack Meridian Health
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
05/23
11/24
NCT03379428: Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active, not recruiting
1/2
26
US
Trastuzumab, Herceptin, Ibrutinib 560 mg, Imbruvica, PCI-32765, Ibrutinib 840 mg, Ibrutinib 420 mg
US Oncology Research, AbbVie, Pharmacyclics LLC.
Breast Neoplasms, Malignant Neoplasm of Breast
06/24
06/24
NCT06357676: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Not yet recruiting
1/2
27
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
OHSU Knight Cancer Institute, Oregon Health and Science University, Genentech, Inc.
Mantle Cell Lymphoma
05/27
05/29
NCT03129828 / 2015-003429-32: Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

Active, not recruiting
1/2
34
Europe
Ibrutinib and Bortezomib + R-CHOP, Ibrutinib (Imbruvica®), Bortezomib (Velcade®)
Prof. Dr. Clemens Schmitt, Charite University, Berlin, Germany, Janssen-Cilag Ltd.
Diffuse Large B Cell Lymphoma
06/24
01/25
NCT03088878: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Active, not recruiting
1/2
102
US
Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, UC-961, Imbruvica, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib, Cirmtuzumab (RDR) plus ibrutinib, Cirmtuzumab plus ibrutinib, Ibrutinib alone
Oncternal Therapeutics, Inc, California Institute for Regenerative Medicine (CIRM), University of California, San Diego, Pharmacyclics LLC.
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
08/24
08/24
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting
1/2
123
RoW
APG-2575, Rituximab, Ibrutinib
Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/25
NCT03153202: Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Recruiting
1/2
21
US
Ibrutinib, Pembrolizumab
Joshua Brody, Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
12/25
12/25
NCT03790332 / 2017-004558-41: Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Active, not recruiting
1/2
59
Europe, Canada, US, RoW
Ibrutinib, IMBRUVICA®, PCI-32765
Pharmacyclics LLC., Janssen Research & Development, LLC
Chronic Graft Versus Host Disease
01/26
01/26
 

Download Options